Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

Review on Treatment of Skin Through Transdermal Patches Interacted with Nanoparticles

Santhosh.B, Kavitha.R*, Damodharan.N

Department of Pharmaceutics, SRM College of Pharmacy, SRMIST, India.
kavithar@srmist.edu.in

Transdermal drug delivery systems, particularly transdermal patches, offer a non-invasive and controlled method for systemic drug administration. Recent advancements in nanotechnology have significantly enhanced the efficacy and scope of these systems through the incorporation of nanoparticles. Nanoparticles, due to its vast surface area and compact size, provide several benefits, including improved drug solubility, stability, and bioavailability. This abstract explores the integration of nanoparticles in transdermal patches, highlighting their potential to overcome traditional barriers such as the skin's stratum corneum, ensuring more effective drug delivery. Key advantages of nanoparticle-loaded transdermal patches include sustained release profiles, minimized adverse effects and focused delivery. Different kinds of nanoparticles, include liposomes, niosomes, solid lipid nanoparticles, and polymeric nanoparticles have been employed, each offering unique properties that can be tailored to specific therapeutic needs. The enhanced permeation and retention (EPR) effect facilitated by nanoparticles further aids in achieving efficient transdermal delivery. Despite promising results, challenges such as skin irritation, long-term safety, and large-scale manufacturing remain to be addressed. Ongoing research focuses on optimizing nanoparticle formulations, understanding the interaction mechanisms with skin tissues, and developing scalable production techniques. The future of transdermal patches with nanoparticles holds significant potential for revolutionizing the management of a number of ailments, providing a patient-friendly substitute for conventional medication administration techniques.

Keywords: Transdermal drug delivery, Nanoparticles, Transdermal patches, Bioavailability, Sustained release.

1. Introduction

The emergence of alternative drug delivery processes for medicinal compounds that are currently in use has attracted considerable attention in the last few years. The creation of an innovative delivery method for already-approved medication molecules enhances the drug's effectiveness and safety while also significantly increasing patient compliance and the overall therapeutic benefit [1]. Employing the cutting-edge ideas of gastro-resistant delivery, pulsatile or controlled release, Therapeutics can be more efficiently given with better absorption if they either entirely or partially degrade before reaching the site of action. Innovative delivery systems can address some of the drawbacks of traditional distribution techniques when they are formulated and developed appropriately for a given drug [1].

Topical and transdermal formulations are the two primary categories into which the skin surface formulations fall. Without exposing the body, topical formulations provide medication to a specific area of the skin. Contrarily, transdermal preparations minimize local impact by delivering effective medication concentrations into systemic circulation. A patch is the most practical formulation for transdermal administration in terms of ease of application, productivity, and manufacturing cost. Transdermal patches are also often well-received and a superior alternative to oral administration in situations when it is difficult for the patient to swallow, may cause irregular assimilation (such as queasiness or sickness), or is unconscious. Drug-in-adhesive (a DIA) reservoirs, matrix of polymers monolithic or multi-laminate, and micro reservoir transdermal patches are the three basic categories, respectively [2]. An active material, additives, a pressurized adhesive (PSA) backing sheet, and an escape wrapping make up a monolithic DIA patch as well. Because of its compact size and thickness, increased flexibility, easy-to-manufacture process, uncomplicated design, and preference among patients, the DIA patch system is superior to other patches. Additionally, cutting or dividing the patch makes it simple to change the dosage, for patients with compromised renal or hepatic functions, for example. When applying the DIA patch system, the drug's integrated adhesive layer comes into touch with the skin's surface. As such, choosing the right adhesive is crucial. Polyisobutylenes, silicones, and acrylics are common PSA polymers used in transdermal DIA patches. The barrier that only lets lipophilic medications penetrate the stratum corneum, regularly referred to be the corneum, the skin's outermost layer with small molecular weights (less than 500 Dalton) to move through the passive diffusion process and, at the necessary amount, enter into the systemic circulation. As a result, there are limits on the quantity of transdermal pharmaceutical systems (TPS) that can be sold. To increase medication penetration through the skin and achieve a therapeutic concentration in the blood, two methods are currently being used: chemical and physical. The method most frequently considered for the manufacture of effective DIA patches is the chemical one, utilizing penetration enhancers (PEs) [2].

Nanospheres, a matrix structure for spreading functional biological components, and nanocapsules, a membrane structure with an aqueous or oily core to contain pharmaceuticals, are two more classifications for nanoparticles (NPs) based on their characteristics, forms, and sizes. NPs alter the pharmacokinetics, cytotoxicity, half-life, permeability, and half-life of drugs and diagnostic agents. They may function as drug transporters, diagnostic agents, or nanosensors. In order to preserve homeostasis, research has focused on enhancing absorption via the skin utilizing polymers, liposomes, or micelles. The goal of research has been to use

polymers, liposomes, or micelles to improve skin absorption and preserve homeostasis. The skin can be penetrated by NPs by intracellular, intercellular, or transcellular pathways. The penetration depth of NPs is dictated by their particle size, which is started by hair movement within the follicle. For certain NPs, a particle size of 600 nm may be ideal. However, penetration is determined by the composition of the NPs. The permeability pictures of 30 nm cadmium selenide/zinc sulfide (CS/ZnSO4) nanoparticles via mouse epidermal disruption caused by ultraviolet light (UV)-B radiation showed that these nanoparticles are aggregated in the skin and sebaceous glands. In this investigation, the interstitium of the epidermis was where NPs were most frequently found [3].

A new class of colloidal nanoparticles known as "patchy nanoparticles" (NPs) have regions of topological or chemical reactions on their surface that are site-specific. Because the surface patches exhibit distinct chemical in terms of its the polarity of usefulness, and composition and/or physical (e.g., form, stiffness, charge, conductivity) features, patchy NPs are attractive for a wide range of applications. These uneven NPs have a variety of uses, including building blocks for constructing intricate structures, biomedical delivery systems, catalysts for nanoreactors, self-moving nanomotors, and interfacial stabilizers. Specific and directed interactions among patches of neighbouring NPs arise when the patches are attractive or chemical firm directing the measurable assembling of NPs into exact yet intricate building patterns (e.g., colloidal molecules). More and more work has been focused on creating chemical patches on the artificial NPs' surface as they generated (such as metallic material, semi-conductive, and magnetized NPs) with precise patch numbers and positions. Typical fabrication techniques include encapsulating NPs over DNA (Deoxyribonucleic acid) frames using phase-separating mixed tiny molecular and/or polymeric bindings upon NPs, and predefined chemical patches, Regioselective surface modification of NPs with mask support, and regulated subsequent material development and nucleation upon seed NPs [3].

Since TDD (Transdermal drug delivery) systems are thought to be user-friendly since they are non-invasive, have no need for expert administration, lessen gastrointestinal (GI) adverse reactions, and enhance adherence among patients [2]. Additionally, because they circumvent the metabolic routes that oral delivery demonstrates, bioavailability, efficacy, and localization are all enhanced. Additionally, this removes the need for intrusive, uncomfortable needles that produce medical waste, carry a risk of infection, and require administration by individuals with medical training. Potentially reactivity or discomfort of the skin, clinging pain, inadequate skin adherence, expense, and specificity for the particular pharmacological drug features are some drawbacks of transdermal medication delivery [3].

BENIFITS OF A TRNSDERMAL MEDICATION DELIVERY SYSTEM

The transdermal application method is a convenient and secure delivery method, making it an intriguing choice.

Transdermal approaches to drug delivery offer numerous incentives, including preventing gastrointestinal incompatibilities and first-pass metabolism, which guarantees that the medicine hits the circulation instantly. These methods offer a noticeable and extended duration of action, which lowers the frequency of dosage and any unfavourable negative effects. They allow the use of drugs with a short biological half-life and a narrow therapeutic

window, improving drug and metabolic reactions and avoiding variations in medication levels [4]. This strategy maintains the plasma concentration of potent drugs while also taking patient variations into consideration. By doing away with the requirement for various dose profiles, it increases patient compliance by enabling more accurate delivery to specified regions. Transdermal systems additionally enhance treatment effectiveness by providing self-administration suitability and the freedom to stop therapy if needed [3].

DISADVANTAGES OF A TRANSDERMAL MEDICATION DELIVERY SYSTEM

Only effective medications should be delivered transdermally, as certain individuals may have skin irritation at the place of application site. If the drug attaches to the skin, there is a chance of dumping the dosage, and the procedure is frequently not lucrative [3]. Rather of addressing acute diseases, it works more effectively for managing chronic ailments including diabetes, hypertension, and angina. The pharmacological effectiveness of the medicine may be affected by cutaneous metabolism, hence transdermal therapy is not advised while using ionic pharmaceuticals. It also works well with drugs that have a smaller molecular mass, generally less than 500 Daltons [4].

LIMITATION OF TRANSDERMAL DRUG DELIVERY SYSTEM

Transdermal therapy cannot deliver drugs that require to be at high blood levels, nor is it practical or cost-effective for providing large doses of medicines through the skin. Irritation or sensitization is one possible adverse effect of a pharmaceutical formulation. Transdermal administration is not a viable option for medications that undergo major skin metabolism or have a molecular size that renders it impossible for them to pass through the skin [4]. Prescription medications without a positive coefficient of partition on oil/water are also not a good fit for it. The effectiveness of the barrier formed by the epidermis is further complicated by the fact that its properties differ from person to person, with age, and from site to site on the same individual [5].

DIFFERENT ADMINSTRATION ROUTES OF NANOPARTICLES

Adminstration Routes	Microneedles	Oral	Intravenous	Topical	Reference
Advantages	• No discomfort • Independent adminstration • Facilitating regional medication distribution	• simple to operate • No discomfort	• Elevated Absorbance.	• simple to operate • No discomfort	[6]
Drawbacks	• Dosage restriction for medications.	• Limited capacity to absorb. • Inadequate allocation.	• A decrease in patient adherence • Toxicology systemic • discomfort	• Limited capacity to absorb • Absorption is incredibly low	[7]

FUNDAMENTAL OF TRANSDERMAL DELIVERY

The skin presents itself as a potential route for drug delivery because it is the biggest and most easily obtainable organ in the body of a person. Because of this, it has undergone considerable investigation, and its biological makeup is well known. Three layers make up the structure of the skin: the dermis, the epidermis, and the subcutaneous "fat" tissue. Two

primary layers make up the epidermis: the viable epidermis (VE) and the stratum corneum (SC). The stratum corneum, measuring 10–20 mm in thickness, is made up of intercellular lamellar lipid bilayers that function as the skin's outer layer and dead, apoptotic, keratin-rich cells called keratinocytes. It is estimated that the membrane of lipids is less than 100 nm broad and is mainly composed of ceramides (50%) and cholesterol (25%). It also contains various free fatty acids [8].



Figure:1 Structure of skin

The SC is referred to as possessing a "brick-and-mortar" structure because the lengthy, slender, tile-like shape of the corneocytes performs the vast majority of the barrier function of the skin. Approximately 100-150 µm thick, the VE (viable epidermis) is composed of keratinocytes that lie beneath the SC. The SC (stratum corneum) is created when these cells keep multiplying and bring aging cells to the outside so they can be subjected to controlled cell death as well as a process of Keratinization." At the site of infection, keratinocytes have the ability to create chemokines and cytokines that enhance immune response [9]. This signalling may lead to the recruitment of patrolling dendritic cells. The intermediate layer of skin is followed by the ~1200 µm-thick dermis. It is constructed up of glycosaminoglycan matrix, collagen, elastin, and fibronectin-containing connective tissue. In addition, it is dotted with sweat glands, sebaceous glands, hair follicles, blood and lymphatic arteries, and nerve endings. Hair follicles and sweat ducts now provide the appendageal channel of skin permeation, forming an immediate interconnecting path between the dermis towards the skin's base while evading the stratum corneum. The superficial fascia, or loose adipose as well as connective tissue located under the dermis, which connects and stabilizes the layer of skin along with muscle, is the subcutaneous "fat" tissue. The cytoplasm has a lipoidal appearance because the cells that make up this composition have high fat content. The epidermis and dermis are connected to the underlying skin tissues by the collagen found in

the spaces between fat cells [8].

KINDS OF PATCHES USED ON THE SKIN [9]

- Single-layer drug-in-adhesive.
- Multi-layer drug-in-adhesive.
- Reservoir.
- Matrix.
- Vapour patch.

1.Single-layer drug-in-adhesive:

Thus, medication is included directly into the skin-contacting adhesive, which sets it apart. Using an adhesive that holds the medication and functions as a skin-adhesion agent which contains numerous excipients in one backing film, the transdermal system design combines two functions into one single product. The rate at which this mechanism releases medication is based on the rate at which the material penetrates the skin [10].

2.Multi-layer drug-in-adhesive:

Although the medication gets incorporated exactly into the adhesive, it is comparable to a single-layered drug-in-adhesive. Between two different drug-in-adhesive films is a membrane or many drug-in-adhesive layers and one backing film are referred to as "multi-layer" combinations [9].

3.Reservoir:

It might be recognized by the fluid compartments that hold a suspension or solution of drug as well as sealed off from the release liner by a sticky, semi-permeable membrane. The product's adhesive component, which controls skin adherence, can be positioned between the release liner and the membrane in a continuous layer or in a concentric pattern around the membrane [9].

fw4.Matrix:

The presence of a semisolid matrix maintaining a pharmaceutical suspension or solution in close contact therewith the release liner may act as a telltale sign. The overlay-incorporated skin-adhering area encircles the semi-solid matrix in a circle [10].

5.Vapour Patch:

The adhesive layer of this sort of patch results in vapour in conjunction with maintaining the several layers together. Vapor patches are newest goods available on the market and they may emit essential oils which lasts up to six hours. Essential oils are released by the vapor patches, they primarily serve to address congestion. Controlled vapour patches, which enhance the overall quality of your sleep, are an option. Additionally, vapour patches are offered to help cut down on the number of cigarettes smoked monthly. Month are offered on the market as well [10].

BASIC PRINCIPALS OF TRANSDERMAL PERMEATION

Passive diffusion serves as the foundation for transdermal penetration. The stratum corneum, or skin permeation barrier, must be penetrated by a topically applied medication before it may work locally or systemically. The principal route for transdermal permeation is the follicular epithelium, which is absorbed via the intact stratum corneum and allows drug molecules to enter the skin through hair follicles or sweat ducts during the first transitory diffusion stage. A number of steps must occur in order for a medicinal agent administered to the skin's layer to be released and transported to the systemic circulation [11]. These processes include;

Dissolution occurs both within and outside of the mixture, enabling the medication to penetrate the stratum corneum, the outermost layer of the skin. The drug then diffuses primarily through a lipidic intercellular route within the stratum corneum. Upon exiting the stratum corneum, the material partitions into the viable epidermis, which is aqueous. It then diffuses across the epidermis and enters the upper dermis, where it is absorbed by the papillary dermis and intact follicular epithelium [12].

CHARACTERISTICS THAT INFLUENCE TRANSDERMAL PENETRATION

FACTORS	EXPLANATIONS	REFERENCES
Physical-chemical characteristics of the molecules that penetrate		
Partition coefficient	• For adequate transdermal permeability, a lipid/water partition coefficient corresponding to one or more is usually needed. • Chemical alteration can change it without compromising the drug's pharmacological action.	[12]
PH conditions	The skin may become damaged by applying solutions with extremely high or low pH values. The transdermal permeability of loaded to unloaded individuals with their ratio can be altered by pH variations, which can impact the flux of ionizable medicines in moderate pH ranges.	[13]
Penetrant concentration	If drug transport is membrane-related, then an increase in drug concentration results in a corresponding increase in flux. Excess solid medication serves as reservoir as well as aids in sustaining in a steady drug composition for an extended amount of time at concentrations greater than solubility.	[13]
Physical-chemical characteristics of the medication delivery		
Release characteristics	Drug's solubility vehicle controls the rate of release. The following variables affect how drugs release: 1. If the drug molecules in the delivery systems are suspended or dissolved. 2. Overall drug's interfacial coefficient of partition between the skin tissue and the delivery device. 3. vehicle's pH.	[14]
Composition of the drug delivery systems	In other ways of impacting the rate of drug discharge, the system for drug delivery features such as boundary layers, thickness, polymers, and vehicles may additionally modify the porosity of the stratum corneum through hydration, interactions contain skin lipids or other elements that promote sorption. For instance, benzocaine permeability	[14]

	drops when using low molecular weight PEG (Polyethylene glycol).	
Enhancement of transdermal permeation	Most medications don't permeate skin well enough to have a therapeutic effect. A permeation promoter can be added to the drug delivery systems to increase penetration and enable most medicines to reach a clinically meaningful level of transdermal permeation.	[12]

PREPARATION OF TRANSDERMAL PATCHES FILMS

Several techniques were used to prepare the transdermal patch film;

1.Mercury Substrate Method:

The way it works incorporates the appropriate amount of drug along with plasticizer in a predetermined amount of polymer solution. After stirring for some time to achieve a uniform dispersion, the solution described above then flows into a glass ring which gets set over the mercury surfaces beneath a glass petri dish. It is permitted to stand unless all of the air bubbles have vanished. The petri dish has been sealed using an inverted funnel in order to control the solvent's pace of evaporation. The dried films require being preserved within a desiccator [15].

2.Circular Teflon Mould Method:

Solutions with varying polymer concentrations are mixed with an organic solvent. The recommended dosage of medicine breaks down in the identical solvent that is organic into half. A drug polymer solution has plasticizer added to it. Pour the entire mixture into a circular Teflon Mold after stirring it thoroughly. Additionally, the Teflon Mold's inverted glass funnel was used to control the pace of solvent vaporization. A 24-hour evaporation period is given to the solvent. The desiccator is where the dried films should be kept [12,14].

3.Glass Substrate Method:

The medication solution and plasticizer should be added shortly after the polymeric solutions have had time to expand. Swirl for 10 minutes. To ensure that no trapped air remains, it is further left aside for a while before being transferred into a dry, clean anumbra Petriplate. For oversight of the rate in which the solvent evaporates out of the petriplate, place a turned-down glass funnel over it. The dry films are removed and placed in a desiccator after being left overnight [15].

4. By Using IPM Membranes Method:

The drug is dissolved in a propylene glycol along with water solution which contains carbomer 940 polymers utilizing a magnetic stirrer and the combination is agitated for a duration of 12 hours. The use of triethanolamine is intended to neutralize the dispersion and increase its viscosity. If the medication is very weakly soluble in a water-based solution, solution gel can be formed by employing buffer pH 7.4. The IPM (Isopropyl Ester) membrane will include the form of gel which generated [15].

5. By Using EVAC Membranes Method:

Rate control membranes made of polyethylene (PE), ethylene vinyl acetate copolymer (EVAC), and 1% carbopol reservoir gel could be used to set up the target transdermal treatment system. If the medicine isn't soluble in water, gel is made using propylene glycol; the drug is disintegrating in propylene glycol and added to a compound containing carbopol resin, which is then neutralized with 5% w/w sodium hydroxide solution. The medication is placed upon a backing layer sheet that encompasses the specific region (in gel form). An apparatus that prevents leaks will be created by covering the gel with a rate-regulating membrane and using heat to seal the edges [15].

6. Aluminium Backed Adhesive Film Method:

When more than 10 mg of medication is loaded into a transdermal device, unstable matrices might be created. The sticky film examine with aluminum backing is a good one.

Since most medicines and adhesives dissolve in chloroform, it is the solvent of choice for producing the same. Adhesive material is introduced and dissolved in the drug combination after the medication has been dissolved in chloroform. Tiny, firmly fitting cork blocks are utilized to appear empty out the ends of an aluminium former that has been carefully constructed and coated using aluminium foil [16].

7. Asymmetric TPX Membrane Method:

One potential material for the backing membrane of a prototype patch includes heat-sealable polyester film (type 1009, 3m), which features a concave diameter approximately one centimetre. The drug mixture has been distributed across the concave membrane, capped with an asymmetric TPX {poly (4-methyl-1-pentene)} membrane and coated with an adhesive [16].

THE CIRCUMSTANCES UNDER WHICH TRANSDERMAL PATCHES ARE USED

Use of transdermal patches occurs when [16]:

1. when the patient requests an alternate drug delivery method due to unpleasant side effects, such as constipation, or because they are unable to swallow their prescription orally (dysphagia).

2. where effective administration could potentially improve pain control. People who are unable to take their analgesia for self-medication nor who have cognitive impairment for various reasons may find this helpful.

THE CIRCUMSTANCES UNDER WHICH TRANSDERMAL PATCHES ARE NOT USED

It is not advisable to use a transdermal patch when [16]:

1. It is necessary to alleviate acute pain.
2. When a quick dose titration is necessary.
3. When the dosage requirement is 30 mg or less per 24 hours or less.

PREPARATION OF NANOPARTICLES

The drug to be packed and the polymer's physical and chemical properties determine which

approach is best for creating nanoparticles. The following are the main ways that nanoparticles are prepared [17]:

1. Emulsion-Solvent Evaporation Method:

Usually, this procedure assists in preparing the nanoparticles. There mainly consist of two phases in this process. The polymer solution must be emulsified as the initial phase of an aqueous phase. The second step takes place when the polymer solution dries and the polymer precipitates, forming nanospheres as a result. Ultracentrifugation is used to gather the nanoparticles, and they are then washed with purified water to remove any leftover medicine or residue, they are stored by lyophilization, a method referred to as solvent evaporation and high-pressure emulsification [18]. The method for eliminating organic solvent entails homogenization at high pressure and continuous stirring. Size may be controlled by varying the ambient temperature, agitation rate, quantity and kind of dispersion agent, and viscous of both the aqueous and organic phases. However, this method can be used with lipid-soluble medications, and restrictions are imposed by the scaling up process. The polymers that are employed in the above process are PLA (The polymer, polylactic acid, polylactide), Poly (β-hydroxybutyrate) (PHB), Poly (caprolactone) (PCL), PLGA (polylactic-co-glycolic acid), cellulose acetate phthalate, and EC (Ethyl cellulose) [17].

2. Double Emulsion and Evaporation Method:

This method's main flaw is how badly hydrophilic medications are confined. Because of this, hydrophilic medications are encapsulated via the double emulsion process. This method involves vigorously churning an organic polymer solution and adding aqueous drug solutions to create w/o emulsions. This w/o emulsion is incorporated to a different aqueous phase once it has been continually agitated to produce a w/o/w mixed emulsion. The solvent is subsequently eliminated by evaporation, and quick centrifuging can be employed to separate the nanoparticles. It is necessary to wash the produced nanoparticles prior to lyophilization. The variables in the above procedure are the concentration of the stabilizer, the total amount of the aqueous phase, the total amount of polymer, and the quantity of hydrophilic medicine. The properties of nanoparticles also get affected by these variables as well [18].

3. Salting Out Method:

The technique of salting out of an aqueous solution is how the water-miscible solvent is separated. Following the dissolution of polyvinylpyrrolidone (PVP) or hydroxyethyl cellulose to serve as colloidal stabilizer in a solvent, the salting-out agent—electrolytes, such as calcium chloride, magnesium chloride, or sucrose as a non-electrolyte—is added to produce an emulsified aqueous gel. For the purpose to boost the solvent's diffusion and demonstrate the development of nanospheres, this oil in water emulsion is diluted via water or aqueous phases. The internal/external phase ratio that occurs, agitation rate, stabilizer type, polymer content in the organic phase, and electrolyte concentration are among the factors that may be adjusted. This method yields highly efficient and easily adjustable nanospheres that consist of PLA, poly(methacrylic) acids, and ethyl cellulose. Since salting out doesn't need a rise in temperature, it might be helpful for materials that are sensitive to heat. The fact that this method is limited to lipophilic medications and necessitates extensive cleaning of nanoparticles are among its drawbacks [18][19].

4. Emulsions Diffusion Method:

The emulsions diffusion method is another often utilized approach for synthesizing nanoparticles. Whenever the solvent intended to dissolve the encapsulating polymer is somewhat miscible when mixed with water, such benzyl alcohol or propylene carbonate, it is crucial to ensure that the initial thermodynamic balance between the two liquids saturated with water. Based on the oil to polymer ratio, nanospheres or nanocapsules are produced when the solvent phase, saturated with water and polymer, gets emulsified over an aqueous solution including stabilizer. Solvent diffusion to the outer phase is brought about by this mechanism. The solvent is then finally removed via filtering or evaporation in line with the point of boiling. This technique has several advantages, including excellent batch-to-batch reproducibility, low homogenization requirements, high encapsulation efficiency (about 70%), simplicity, limited size dispersion, and ease of scaling up [19].

However, there are a number of disadvantages to this approach, such as the large amounts of water that must be eliminated from the suspension and the reduced effectiveness of encapsulation during emulsification due to water-soluble drug leakage in the saturated-aqueous outer phase. Mesotetra (hydroxyphenyl) porphyrin-loaded PLGA (p-THPP) nanoparticles, doxorubicin-loaded PLGA nanoparticles, loaded sodium glycolate nanoparticles, and cyclosporine (cy-A-) nanoparticles were all produced via this method [18].

5.Solvent Displacement/Precipitation method:

The dispersion of the solvent that is organic in an aqueous medium—either with or without the addition of a surfactant—and the precipitation of a produced polymer from an organic solution are two steps in the solvent displacement process. Drugs, polymers, and lipophilic surfactants are dissolved in acetone or ethanol, two semi-polar water miscible solvents. After that, the prepared solution is either injected or poured into the stabilizer holding the aqueous solution all while being magnetically agitated. The rapid diffusion of solvent enhances the formation of nanoparticles. The solvent is then removed at reduced pressure from the suspension. Particle size is also influenced by the rate of addition of the organic phase over the aqueous phase. It was demonstrated that drug trapping and particle size decreased with increasing mixing rate. Most drugs that are poorly soluble can be successfully treated using nano precipitation. By altering the preparation conditions, effective control over drug release and nanosphere size may be obtained. While adjusting the concentration of the polymer generates an adequate amount of smaller nanospheres [19].

6. Polymerization method:

The medication is absorbed into the polymerization medium either by dissolving in it or by adsorbing onto the nanoparticles after the monomers are polymerized in an aqueous solution using this approach. After that, to remove the different stabilizers and surfactants, the nanoparticle mixture is filtered then reintroduced using an isotonic surfactant-free medium that were utilized during the ultra-centrifugation polymerization process. It has been published how to make poly (alkyl cyanoacrylate) or polybutyl cyanoacrylate nanoparticles. The number of surfactants and stabilizers utilized has an impact on the formation of nanocapsules and the size of their particles [19].

7. Coacervation or ionic gelation method:

Numerous investigations regarding biodegradable hydrophilic polymers are currently carried out, including chitosan, sodium alginate, and gelatin, to produce nanoparticles. A process created by Calvo and associates for ionic gelation to produce hydrophilic chitosan nanoparticles. A polyanion (sodium tripolyphosphate) and the polymer chitosan make up the two aqueous phases of the procedure. In this reaction, the negatively charged tri polyphosphate and the positively charged amino group of chitosan incorporate to produce coacervates ranging in size from anometer to one. Ionic gelation is the process by which a liquid at room temperature changes from a liquid due to ionic contact conditions, Conversely, cognates are created as an outcome of two aqueous phases coming into electrostatic contact [18,19].

TRANSDERAMAL NANOCARRIERS FOR THE TREATMENT OF SKIN DISEASES

Three classifications: liquid, crystalline, or solid phase nanocarriers can be used to categorize the diverse range of nanocarriers utilized in TDD research. Solid phase nanocarriers, such as solid polymeric, solid lipid, and metal core nanoparticles, often exhibit the slowest rate of drug dissociation. The majority of liquid phase nanocarriers are made up of lipid nanoemulsions and micelles that have a melting point lower than the average body temperature. Liquid phase nanocarriers release pharmaceuticals substantially more quickly than solid phase nanocarriers primarily because of their less structured lipid coating. Furthermore, recent research has demonstrated that liposomes may enhance penetration however fail to transport medications across the stratum corneum. Typically, monolein, water, and poloxamer are used to form the less frequent liquid crystalline nanodispersions, which result in a better structured fluid lipid nanoparticle than traditional micelles [19].

Psoriasis and atopic dermatitis are currently treated using topical applications of immunosuppressive calcineurin inhibitors; nevertheless, skin penetration and off-target immunomodulatory effects remain a problem. A calcineurin inhibitor called tacrolimus lowers T cell activity in inflammatory skin conditions. Lapteva et al. showed that when loading tacrolimus into 10–50 nm polymeric micelles, the medication was able to penetrate the uppermost layer of human ex vivo epidermis more effectively than when the drug was administered without a nanocarrier [18].
The research also contains examples of medicines that are not being used for healing inflammatory skin conditions; however, they are also employed as nanocarriers in treating skin conditions in animal models. For instance, 200 nm chitosan nanoparticles containing the non-steroidal anti-inflammatory medication ketoprofen were utilized to treat a C57BL/6 (C57 BLACK 6) mouse model of psoriasis that was produced by imiquimod. Comparing the treatment with the nanocarrier to the medication without, the researchers saw decreased transepidermal water loss, enhanced drug penetration into the skin, and lower release of IL-17 (Interleukin-17) and IL-23 (Interleukin-23). Ceramides are another potentially ground-breaking treatment for skin disorders. They belong to the lipid structure which constitutes the appropriate stratum corneum. Jung et al. successfully cured a model of rat atopic dermatitis caused by sodium dodecyl sulfate (SDS) by employing 200-nm chitosan nanoparticles loaded with ceramides. The stratum corneum of the rat model showed signs of healing after ceramide therapy in the nanocarrier Conversely, Keck et al. used 200-nm nanolipid

compounds with electrostatically linked silver ions to show anti-microbial and anti-inflammatory properties in a DNFB (Dinitrofluorobenzene)-induced animal model of atopic dermatitis [20]. It is commonly known that silver ions have antimicrobial properties. Finally, Certain nanoparticles might have an immunosuppressive impact if given without medicine. When C60 fullerenes (Buckminster fullerene) were used topically to a mouse form of atopic dermatitis provoked by ovalbumin, Shershakova et al. saw improvements in histological results along with a decrease in IgE (Immunoglobin E) production and cytokines. Nanosized zinc oxide nanoparticles have been demonstrated to have a similar effect; however, in addition to reducing swelling linked to in mice having atopic dermatitis produced on by ovalbumin/staphylococcal enterotoxin B, zinc oxide also increased IgE levels. Research that is being reviewed in our lab also shows how tiny negatively charged nanoparticles, such as gold nanoparticles, quantum dots, or silica nanospheres, might lessen skin edema and inflammation in a contact dermatitis model in animals (20–150 nm). There are other medications and substances that have not yet received approval that may be used to treat skin inflammatory illnesses [20].

One interesting use of TDD for the management of skin conditions is nanocarriers because they offer the possibility of lower drug concentrations or application intervals, the introduction of new procedures which were already underutilized due to low transdermal penetration, and an observed boost in drug skin penetration and skin targeting. But additional investigation is required into the relationship between skin illness and nanocarriers. Numerous studies are proof of concept investigations, which only show how well nanocarriers may increase a drug's penetration or retention in the skin. In vivo models of skin illness were utilized in many of the research that were reviewed; nevertheless, most of the time, when compared to psoriasis or atopic dermatitis, the models more precisely reflected allergic contact dermatitis or irritating dermatitis. Psoriasis and atopic dermatitis can be driven by genetic along with environmental variables, leading to far more challenging disease phenotypes than those simulated through using a chemical sensitizer. To better form conclusions the results for potential human usage, further extensive testing of nanocarriers using genetic animal knockout models of psoriasis and atopic dermatitis is needed [19].

2. Discussion

Since skin administration of medication is less painful than injection, avoids the liver's first pass metabolism, and may be designed for a gradual and continuous release of medication into the systemic circulation, nanocarriers are being studied for several uses in TDD. For these reasons, transdermal distribution of immunizations, antihypertensive medications, antiparkinsonian medications, and chemotherapy has been studied using nanocarriers. Nonetheless, as this illustration shows, intact skin may be penetrated by nanoparticles in a way that depends on their size, charge, and composition. Healthy skin acts as a physical barrier against xenobiotic chemicals and particulates. Skin barrier abnormalities like psoriasis and atopic dermatitis are treated well with nanocarriers because they disturb the skin barrier and increase the penetration of nanoparticles [13].

The physical and chemical characteristics of biological milieus determine how nanocarrier cells assimilate and deal with them. The main physicochemical properties of nanoparticles

which impact their absorption by cells are their dimensions, form, firmness, and energy on the surface. There are a number of advantages and disadvantages of employing nanocarriers for transdermal drug administration, most of which are linked to their small size, substantial surface energy, substance, architecture, and linked molecules [6]. It appears optimistic that more and more nanocarriers are being utilized to subcutaneously apply siRNA (Small interfering RNA) to the skin in an attempt to quiet specific genes that contribute to skin conditions [11]. This indicates a move in the industry toward targeted genetic treatments in addition to demonstrating the potential to increase the ability of larger macromolecules to penetrate the skin with the aid of nanocarriers. Such therapies might be customized to meet the needs of each patient in order to optimize improvement. Due to variations in the interplay between genes and environment, the phenotype of atopic dermatitis and psoriasis can be diverse. Although there will be no cure, this treatment may also help with symptoms when compared to existing treatments [20].

Future Prospects:

The future of transdermal patches with nanoparticles is promising, with ongoing research focused on overcoming existing challenges. Recent advancements in materials science have led to the development of novel materials and nanoparticles that significantly enhance drug loading, stability, and skin penetration in transdermal patches. This progress enables the customization of nanoparticle-based transdermal patches for personalized medicine, optimizing drug delivery to meet specific patient needs. Additionally, research into combination therapies is gaining momentum, as nanoparticles are being explored in conjunction with other therapeutic modalities, such as microneedles or iontophoresis, to further improve drug delivery efficacy. These innovations are expanding the applications of transdermal patches, allowing for a broader range of drugs and conditions to be effectively treated with this technology.

In conclusion, transdermal patches with nanoparticles hold great potential to revolutionize drug delivery, offering enhanced efficacy, safety, and patient convenience. Continued research and development, along with addressing resolving these current difficulties will be important for attaining their full potential and translating laboratory successes into clinical and commercial realities.

3. Conclusion

Transdermal patches with nanoparticles represent a promising advancement in drug delivery systems. Their capacity to improve medication absorption via the skin, provide controlled and sustained release, and target specific sites makes them an attractive alternative to traditional delivery methods. Overall, transdermal patches with nanoparticles hold significant potential to revolutionize the field of medicine, offering a non-invasive, efficient, and patient-friendly approach to drug administration. Transdermal patches with nanoparticles represent a cutting-edge advancement in drug delivery, offering several key findings and outcomes.

Nanoparticles significantly enhance drug delivery by improving the permeability of drugs through the skin, enabling more efficient and targeted delivery of active pharmaceutical

ingredients. The incorporation of nanoparticles also allows for controlled release, ensuring consistent therapeutic effects and reducing side effects. Transdermal patches offer a non-invasive administration route, enhancing patient compliance and comfort compared to oral or injectable methods. Additionally, these patches bypass the liver's first-pass metabolism by delivering drugs directly through the skin, which can potentially enhance drug bioavailability.

ACKNOWLEDGEMENT

The authors are grateful to thank SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, for providing the required facility and support to carry out this review work.

References

1. Sun Y, Fang L, Zhu M, Li W, Meng P, Li L, He Z: A drug-in-adhesive transdermal patch for S-amlodipine free base: In vitro and in vivo characterization. Int J Pharm. 2009, 382:165–71. 10.1016/j.ijpharm.2009.08.031
2. Economidou SN, Lamprou DA, Douroumis D: 3D printing applications for transdermal drug delivery. Int J Pharm. 2018, 544:415–24. 10.1016/j.ijpharm.2018.01.031
3. Guy RH, Hadgraft J, Bucks DAW: Transdermal drug delivery and cutaneous metabolism. Xenobiotica. 1987, 17:325–43. 10.3109/00498258709043943
4. K Purushotham, K Anie Vijetha: A review on transdermal drug delivery system. GSC Biological and Pharmaceutical Sciences. 2023, 22:245–55. 10.30574/gscbps.2023.22.2.0053
5. Baetke SC, Lammers T, Kiessling F: Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 2015, 88:20150207. 10.1259/bjr.20150207
6. Li W, Terry RN, Tang J, Feng MR, Schwendeman SP, Prausnitz MR: Rapidly separable microneedle patch for the sustained release of a contraceptive. Nat Biomed Eng. 2019, 3:220–9. 10.1038/s41551-018-0337-4
7. Zhu M, Liu Y, Jiang F, Cao J, Kundu SC, Lu S: Combined Silk Fibroin Microneedles for Insulin Delivery. ACS Biomater Sci Eng. 2020, 6:3422–9. 10.1021/acsbiomaterials.0c00273
8. Palmer B, DeLouise L: Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting. Molecules. 2016, 21:1719. 10.3390/molecules21121719
9. N.K.Jain: Controlled and novel drug delivery - Hardcover. 2019th ed. CBS publishers and distributors pvt Ltd. India; 2019.
10. Mathiowitz E, Chickering III DE, Lehr C-M, editors: Bioadhesive Drug Delivery Systems. CRC Press; 1999. 10.1201/9780367800758
11. Walters KA, Roberts MS, editors: Dermatologic, Cosmeceutic, and Cosmetic Development. CRC Press; 2007. 10.3109/9780849375903
12. Pawan Jalwal, Anju Jangara, Lalita Dahiya: A Review on transdermal patches. The Pharma Research. 2009, 139–49.
13. Govil SK, Tyle P: Drug Delivery: Fundamentals and Application. Res J Pharm Technol. 1988, 385–406.
14. Choudhary N, Singh AP: Transdermal drug delivery system: A review. Indian Journal of Pharmacy and Pharmacology. 2021, 8:5–9. 10.18231/j.ijpp.2021.002
15. Aqil M, Sultana Y, Ali A: Transdermal delivery of β-blockers. Expert Opin Drug Deliv. 2006, 3:405–18. 10.1517/17425247.3.3.405
16. Monkhouse DC, Huq AS: Transdermal Drug Delivery - Problems and Promises. Drug Dev Ind Pharm. 1988, 14:183–209. 10.3109/03639048809151970

17. Kumari B: "A REVIEW ON NANOPARTICLES: THEIR PREPARATION METHOD AND APPLICATIONS". Indian Research Journal of Pharmacy and Science. 2018, 5:1420–6. 10.21276/irjps.2018.5.2.3
18. Yoo HS, Oh JE, Lee KH, Park TG: Biodegradable nanoparticles containing doxorubicin-PLGA. Pharm Res. 1999, 16:1114–8. 10.1023/A:1018908421434
19. Ilves M, Palomäki J, Vippola M, Lehto M, Savolainen K, Savinko T, Alenius H: Topically applied ZnO nanoparticles suppress allergen induced skin inflammation but induce vigorous IgE production in the atopic dermatitis mouse model. Part Fibre Toxicol. 2014, 11:38. 10.1186/s12989-014-0038-4
20. Keck CM, Anantaworasakul P, Patel M, et al.: A new concept for the treatment of atopic dermatitis: Silver–nanolipid complex (sNLC). Int J Pharm. 2014, 462:44–51. 10.1016/j.ijpharm.2013.12.044